These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38794946)

  • 21. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
    Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
    J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase.
    Usami E; Kimura M; Iwai M; Teramachi H; Yoshimura T
    Mol Clin Oncol; 2017 Jun; 6(6):955-959. PubMed ID: 28588796
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].
    Tatay VS; Castilla JD; Ponce JM; Hurtado JM; Cantero E; Abril ML
    An Pediatr (Barc); 2010 Feb; 72(2):103-10. PubMed ID: 20022572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.
    Eaddy M; Seal B; Tangirala K; Davies EH; O'Day K
    Appl Health Econ Health Policy; 2012 Nov; 10(6):431-40. PubMed ID: 23013428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of single-dose rasburicase in an obese female.
    Arnold TM; Reuter JP; Delman BS; Shanholtz CB
    Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.
    Holdsworth MT; Nguyen P
    Am J Health Syst Pharm; 2003 Nov; 60(21):2213-22; quiz 2223-4. PubMed ID: 14619112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
    Takai M; Yamauchi T; Matsuda Y; Tai K; Ikegaya S; Kishi S; Urasaki Y; Yoshida A; Iwasaki H; Ueda T
    Oncol Lett; 2015 May; 9(5):2119-2125. PubMed ID: 26137024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rasburicase in the prevention of laboratory/clinical tumour lysis syndrome in children with advanced mature B-NHL: a Children's Oncology Group Report.
    Galardy PJ; Hochberg J; Perkins SL; Harrison L; Goldman S; Cairo MS
    Br J Haematol; 2013 Nov; 163(3):365-72. PubMed ID: 24032600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy and cost-impact of rasburicase 3 mg versus 6 mg for the management of tumor lysis syndrome: A multicenter analysis.
    Marjoncu D; Holman K
    J Oncol Pharm Pract; 2023 Jun; 29(4):893-898. PubMed ID: 35306913
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic comparison of rasburicase and allopurinol for treatment of tumor lysis syndrome in pediatric patients.
    Eaddy M; Seal B; Tangirala M; Davies EH; O'Day K
    Am J Health Syst Pharm; 2010 Dec; 67(24):2110-4. PubMed ID: 21116002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
    Bessmertny O; Robitaille LM; Cairo MS
    Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Abbreviated rasburicase dosing for the prevention and treatment of hyperuricemia in adults at risk for tumor lysis syndrome.
    Ho VQ; Wetzstein GA; Patterson SG; Bradbury R
    Support Cancer Ther; 2006 Apr; 3(3):178-82. PubMed ID: 18632493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rasburicase in cancer-related hyperuricemia.
    Rodriguez M; Campara M; Haaf C
    Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pitfalls, prevention, and treatment of hyperuricemia during tumor lysis syndrome in the era of rasburicase (recombinant urate oxidase).
    Pession A; Melchionda F; Castellini C
    Biologics; 2008 Mar; 2(1):129-41. PubMed ID: 19707436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
    Vadhan-Raj S; Fayad LE; Fanale MA; Pro B; Rodriguez A; Hagemeister FB; Bueso-Ramos CE; Zhou X; McLaughlin PW; Fowler N; Shah J; Orlowski RZ; Samaniego F; Wang M; Cortes JE; Younes A; Kwak LW; Sarlis NJ; Romaguera JE
    Ann Oncol; 2012 Jun; 23(6):1640-5. PubMed ID: 22015451
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Interventions to Prevent Tumour Lysis Syndrome in Hematologic Malignancy: A Multisite Retrospective Chart Review.
    McKenna S; Cheung A; Wolfe A; Coleman BL; Detsky ME; Munshi L; Maze D; Burry L
    Can J Hosp Pharm; 2019; 72(6):435-445. PubMed ID: 31853144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rational use of rasburicase for the treatment and management of tumor lysis syndrome.
    Shaikh SA; Marini BL; Hough SM; Perissinotti AJ
    J Oncol Pharm Pract; 2018 Apr; 24(3):176-184. PubMed ID: 28077046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.